外周血淋巴细胞/单核细胞比值、淋巴细胞亚群与去甲基化药物治疗初发骨髓增生异常综合征疗效的相关性研究

Prognostic relevance of lymphocyte-to-monocyte ratio in decitabine and azacitidine in the treatment of myelodysplastic syndrome

目的:探究淋巴细胞/单核细胞比值(LMR)、淋巴细胞亚群与去甲基化药物(HMA)治疗初发骨髓增生异常综合征(MDS)疗效的相关性。方法:收集徐州医科大学附属医院2017年1月—2022年2月收治的72例接受HMA单药治疗的MDS患者。根据首次入院时血常规结果计算得出LMR,并以中位数为临界值,将患者分为高LMR组(LMR≥4.80)36例和低LMR组(LMR<4.80)36例;应用流式细胞术检测外周血淋巴细胞亚群(CD3+T细胞,CD4+T细胞及CD8+T细胞比例),分析LMR与治疗3个疗程后的治疗有效率(ORR)及中位总生存期(OS)的关系;淋巴细胞亚群在HMA治疗前后的变化以及与OS的相关性。结果:高LMR组与低LMR组治疗3个疗程后的中位生存期差异有统计学意义(P=0.036);多因素Cox回归分析显示3个疗程后LMR≥4.80是MDS患者OS的独立影响因素(P<0.05)。HMA治疗后CD8+T细胞比例显著升高(P=0.035)。结论:初发MDS患者LMR与HMA治疗MDS早期疗效及预后有关。患者首次入院的淋巴细胞亚群与HMA治疗MDS预后无明显相关性。

Objective:To explore the correlation between lymphocyte-to-monocyte ratio(LMR),lymphocyte subsets and the efficacy of hypomethylating agent(HMA)in the treatment of primary myelodysplastic syndrome(MDS).Methods:A total of 72 MDS patients who received HMA monotherapy admitted to the Affiliated Hospital of Xuzhou Medical University from January 2017 to February 2022 were collected.LMR was calculated according to the blood routine results at the first admission,and the median was the critical value,and the patients were divided into a high LMR group(LMR≥4.80)with 36 cases and a low LMR group(LMR<4.80)with 36 cases.Cytometry was used to detect lymphocyte subsets in peripheral blood,and the relationship between LMR and related clinical indicators,overall response rate(ORR)after 3 courses of treatment,and median OS were analyzed.Results:Multivariate Cox regression analysis showed that LMR≥4.80 after three courses of treatment was an independent factor for OS in MDS patients after three courses of demethylation drugs(P<0.05),while the proportion of CD3+T cells,CD4+T cells and CD8+T cells was not independent factor for OS in MDS patients treated with HMAs.The proportion of CD8+T cells was increased after treatment of HMAs(P=0.035).Conclusion:LMR in patients with newly diagnosed MDS is related to the early efficacy and prognosis of HMAs in the treatment of MDS.There was no significant correlation between lymphocyte subsets at first admission and the early efficacy of HMAs in the treatment of MDS.